{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Onureg"},{"type":"USBrandName","name":"Vidaza"},{"type":"Synonym","name":"5-AC"},{"type":"Abbreviation","name":"5-AC"},{"type":"Synonym","name":"5-azacytidine"},{"type":"Synonym","name":"azacytidine"},{"type":"Synonym","name":"ladakamycin"},{"type":"ChemicalStructureName","name":"4-amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one"},{"type":"Abbreviation","name":"5-AZC"},{"type":"ObsoleteName","name":"Mylosar"},{"type":"CodeName","name":"U-18496"},{"type":"Synonym","name":"5-azacitidine"},{"type":"CASRegistryName","name":"320-67-2"},{"type":"ChemicalStructureName","name":"5-aza-cytidine"}],"definition":{"html":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation. Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity.","text":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation. Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/azacitidine","text":"Azacitidine"},"nciConceptId":"C288","nciConceptName":"Azacitidine","termId":39153,"name":"azacitidine","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"azacitidine"},{"aliases":[{"type":"CodeName","name":"CC-486"},{"type":"Synonym","name":"azacitidine oral"}],"definition":{"html":"An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.\n","text":"An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C118288","nciConceptName":"Oral Azacitidine","termId":764239,"name":"oral azacitidine","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"oral-azacitidine"}],"links":null}